Science Sub-Journal: Revealing that radiotherapy and immunotherapy restrict tumor progression by removing extramedullary red blood cell precursor cells

February 28, 2021 News/bioon.
com" target="_blank">/---Targeted radiation is often used to research and treat different types of cancer.
In a new study, researchers from China's Xi'an Jiaotong University, Shandong First Medical University, Shandong Qianfoshan Hospital, Xuzhou Medical University, the University of Chicago, and the University of Texas Southwestern Medical Center focused on one type of cell , They release a protein that enhances resistance to cancer therapy and promotes bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor progression.
The relevant research results were published in the journal Science Translational Medicine on February 24, 2021, with the title of the paper "Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity".

The picture comes from CC0 Public Domain.

This research focused on Ter cells, which are extra medullary erythroid precurser cells that secrete the neuropeptide artemin.
These researchers found that local tumor radiation therapy, immunotherapy or systemic combination of the two treatments can be consumed Ter spleen cells, reduce the production of artemin, and tumors outside the radiation field limiting local irradiation of bioon.

These researchers proposed, "In short, our research confirms the opposing regulatory effects between radiotherapy or immunotherapy and bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor- induced splenic Ter cells.
"

These researchers believe that these immunotherapies and combined treatments with radiotherapy are "worthy of further study to understand their interaction with bioon.
com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
html">tumor- promoting pathways.
" (Bioon.
com)

References: 1.
Yuzhu Hou et al.
sciencemag.